AAL

Moderna Stock Soars On Massive COVID-19 Vaccine Study

The equity is up over 300% year-to-date

Digital Content Manager
Jul 27, 2020 at 11:02 AM
facebook X logo linkedin


The shares of Moderna Inc (NASDAQ: MRNA) were last seen up 5.4% at $77.18, after the U.S. government nearly doubled its initial $483 million investment and awarded the biotechnology company an additional $472 million over the weekend to support the development of its potential coronavirus vaccine. The experimental treatment is entering late-stage trials, which will include a stage-three study involving at least 30,000 volunteers. 

Despite this, BMO slashed its price target to $94 from $112 this morning. This puts the consensus 12-month price target at $92.77, which is still a 19.9% premium to current levels. The majority of analysts are optimistic on MRNA, however. Ten consider it a "buy" or better, while just three say "hold," with not a single sell to be seen. 

On the charts, MRNA has slightly cooled off from its all-time high of $95.21 on July 17. Most of these losses were captured by the stock's 40-day moving average, however. Plus, year-to-date, MRNA sports an impressive 301% lead.

In the options pits, it looks as if calls are more than doubling puts. In the last 10 days, 133,137 calls were exchanged, as opposed to 54,149 puts. On the other hand, MRNA's Schaeffer's put/call open interest ratio (SOIR) now stands higher than 90% of readings from the past year, implying short-term options traders have been more put-biased than usual.

 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.